Key Takeaways
- • Hologic completed its $18.3 billion sale to TPG and Blackstone with all regulatory approvals finalized, officially closing on April 7, 2026, and transitioning from public (Nasdaq: HOLX) to private ownership.
- • CEO Steve MacMillan, 62, is retiring effective with the transaction close after 12 years leading the company, during which he increased revenue 65%, earnings per share 184%, and stock price 241% while expanding the workforce by over 1,500 employees.
- • Under MacMillan's tenure since December 2013, Hologic transformed from a turnaround candidate into a global leader in women's health, with the company citing his management of consistent growth, COVID-19 pandemic response, and successful execution of the go-private transaction.
- • Hologic's board plans to announce a successor CEO following the transaction close on Tuesday, April 7; MacMillan previously served as CEO of Stryker before joining Hologic.
Summary
Hologic has secured all necessary regulatory approvals to finalize its $18.3 billion acquisition by private equity firms TPG and Blackstone, with the transaction officially closing on April 7, 2026. The Marlborough, Massachusetts-based breast imaging vendor will cease public trading on the Nasdaq under ticker HOLX upon completion and become a privately held company under PE ownership.
Concurrent with the transaction close, Hologic President and CEO Steve MacMillan announced his retirement after 12 years leading the medical device manufacturer. MacMillan, 62, initially joined Hologic in December 2013 following his tenure as CEO of Stryker, a major medical equipment manufacturer. During his tenure, MacMillan oversaw substantial operational and financial improvements: revenue increased 65%, earnings per share rose 184%, stock price appreciated 241%, and headcount expanded by more than 1,500 employees. According to the company's announcement, these gains reflected both internal turnaround execution and sustained growth trajectory.
Amy Wendell, Hologic's lead independent director, offered formal recognition of MacMillan's leadership in a statement dated April 6. She credited him with orchestrating "a dramatic turnaround shortly after joining the company," maintaining "years of consistent growth," managing the company's "unprecedented response to the COVID pandemic," and successfully navigating "a successful go-private transaction." Wendell characterized MacMillan as "one of the most respected leaders in the medical technology industry."
In his own communications, MacMillan highlighted his role in transforming Hologic into "a global leader in women's health" while driving innovation, growth, and patient impact globally. The company indicated that its board of directors will announce MacMillan's successor following the official close of the TPG-Blackstone transaction on April 7, 2026.
Concurrent with the transaction close, Hologic President and CEO Steve MacMillan announced his retirement after 12 years leading the medical device manufacturer. MacMillan, 62, initially joined Hologic in December 2013 following his tenure as CEO of Stryker, a major medical equipment manufacturer. During his tenure, MacMillan oversaw substantial operational and financial improvements: revenue increased 65%, earnings per share rose 184%, stock price appreciated 241%, and headcount expanded by more than 1,500 employees. According to the company's announcement, these gains reflected both internal turnaround execution and sustained growth trajectory.
Amy Wendell, Hologic's lead independent director, offered formal recognition of MacMillan's leadership in a statement dated April 6. She credited him with orchestrating "a dramatic turnaround shortly after joining the company," maintaining "years of consistent growth," managing the company's "unprecedented response to the COVID pandemic," and successfully navigating "a successful go-private transaction." Wendell characterized MacMillan as "one of the most respected leaders in the medical technology industry."
In his own communications, MacMillan highlighted his role in transforming Hologic into "a global leader in women's health" while driving innovation, growth, and patient impact globally. The company indicated that its board of directors will announce MacMillan's successor following the official close of the TPG-Blackstone transaction on April 7, 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.